<DOC>
	<DOCNO>NCT00563433</DOCNO>
	<brief_summary>224 adult diabetic foot ulcer randomize either magainin peptide ( MSI-78 ) ofloxacin ( FLOXIN , Ortho-McNeil Pharmaceutical Corporation ) oral fluoroquinolone antibiotic .</brief_summary>
	<brief_title>MSI-78 Topical Cream v . Oral Ofloxacin Treatment Infected Diabetic Ulcers</brief_title>
	<detailed_description>Approximately 224 adult enrol outpatient Phase III study compare safety efficacy topically apply magainin peptide ( MSI-78 ) ofloxacin ( FLOXIN , Ortho-McNeil Pharmaceutical Corporation ) oral fluoroquinolone antibiotic , treatment infect diabetic foot ulcer . This randomize , control , double-blind trial involve twenty clinical center .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<criteria>Nonhospitalized ambulatory patient diabetes mellitus Men Women great 18 year old Patients must consider reliable , willing able give consent Female patient must postmenopausal least 6 month surgically sterilize Localized infection ulcer would ordinarily treat outpatient basis Patients previously treat currently treatment localized infection ulcer may enrol adequate response treatment ulcer still infect Patient must radiograph within two week entry show evidence cortical destruction consistent osteomyelitis Patient must palpable dorsalis pedis posterior tibial pulse affect foot Patient may take receive investigational therapy approve therapy within 30 day prior entry Patients require concurrent local systemic antimicrobial study period infection Patients currently treat await dialysis Patients unable care ulcer Patients know alcohol substance abuse within 6 month study entry Patients significant GI problem surgery might interfere absorption ofloxacin Patients currently receive systemic corticosteroid , immunosuppressive , antiviral , radiation therapy cytotoxic agent Patients currently require treatment primary metastatic malignancy systemically immunocompromising disease . Previous enrollment study previous treatment MSI78 Topical Cream Patients gangrene severely impaired arterial supply portion affect foot Other condition consider investigator sound reason disqualification Patients know allergy ofloxacin , quinolone antibiotic , magainin peptide ingredient vehicle cream Women breast feeding , pregnant attempt become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>diabetic</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>foot</keyword>
	<keyword>ulcer</keyword>
	<keyword>Floxin</keyword>
	<keyword>oral antibiotic</keyword>
	<keyword>topical cream</keyword>
</DOC>